Literature DB >> 25133042

Approach to Helicobacter pylori infection in geriatric population.

Sevdenur Cizginer1, Zehra Ordulu1, Abdurrahman Kadayifci1.   

Abstract

The prevalence of Helicobacter pylori (H. pylori) infection and its complications increase with age. The majority of infected individuals remain asymptomatic throughout the life but 10%-20% develops peptic ulcer disease and 1% gastric malignancies. The incidence of ulcers and their complications are more common in the older population resulting in higher hospitalization and mortality rates. The increased use of medications causing gastric mucosal damage and the decreased secretion of protective prostaglandins in elderly are major factors increasing gastric mucosal sensitivity to the destructive effects of H. pylori. Due to higher prevalence of gastrointestinal (GI) malignancies, upper GI endoscopy is mostly preferred in elderly for the diagnosis of infection. Therefore, "endoscopy and treat" strategy may be more appropriate instead of "test and treat" strategy for dyspeptic patients in older age. Urea breath test and stool antigen test can be used for control of eradication, except for special cases requiring follow-up with endoscopy. The indications for treatment and suggested eradication regimens are similar with other age groups; however, the eradication failure may be a more significant problem due to high antibiotic resistance and low compliance rate in elderly. Multidrug usage and drug interactions should always be considered before starting the treatment. This paper reviews briefly the epidemiology, diagnosis, disease manifestations, and treatment options of H. pylori in the geriatric population.

Entities:  

Keywords:  Diagnosis; Elderly; Epidemiology; Eradication; Geriatric population; Geriatrics; Helicobacter pylori; Treatment

Year:  2014        PMID: 25133042      PMCID: PMC4133439          DOI: 10.4292/wjgpt.v5.i3.139

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  105 in total

1.  A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.

Authors:  X Calvet; N García; T López; J P Gisbert; E Gené; M Roque
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

2.  The quality of care for Medicare patients with peptic ulcer disease.

Authors:  J J Ofman; J Etchason; W Alexander; B R Stevens; J Herrin; C Cangialose; D J Ballard; D Bratzler; K S Elward; D FitzGerald; J Culpepper-Morgan; B Marshall
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

3.  High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.

Authors:  J Sánchez-Delgado; P García-Iglesias; M Castro-Fernández; F Bory; M Barenys; L Bujanda; J Lisozain; M M Calvo; S Torra; J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2012-05-17       Impact factor: 8.171

4.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

Review 5.  Helicobacter pylori.

Authors:  B J Marshall
Journal:  Am J Gastroenterol       Date:  1994-08       Impact factor: 10.864

6.  The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine.

Authors:  Mehmet Sait Bugdaci; Sayid Shafi Zuhur; Mehmet Sokmen; Buket Toksoy; Banu Bayraktar; Banu Albayrak; Yüksel Altuntas
Journal:  Helicobacter       Date:  2011-04       Impact factor: 5.753

Review 7.  An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.

Authors:  Paul Moayyedi; Jon Deeks; Nicholas J Talley; Brendan Delaney; David Forman
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

8.  Therapeutic effects of lansoprazole on peptic ulcers in elderly patients.

Authors:  M Murakami; H Saita; Y Takahashi; S Kusaka; K Asagoe; H Dekigai; M Matsumoto; M Seki; M Mizuno; S Maeda
Journal:  J Clin Gastroenterol       Date:  1995       Impact factor: 3.062

Review 9.  Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.

Authors:  Alexander C Ford; Brendan C Delaney; David Forman; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

10.  Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Masayuki Suzuki; Masahiko Takahashi; Toshifumi Hibi
Journal:  J Clin Biochem Nutr       Date:  2012-03-30       Impact factor: 3.114

View more
  8 in total

Review 1.  Current Helicobacter pylori treatment in 2014.

Authors:  Fatih Ermis; Elif Senocak Tasci
Journal:  World J Methodol       Date:  2015-06-26

Review 2.  [Duodenal ulcers, gastric ulcers and Helicobacter pylori].

Authors:  Peter Dovjak
Journal:  Z Gerontol Geriatr       Date:  2017-02-01       Impact factor: 1.281

Review 3.  From the stomach to other organs: Helicobacter pylori and the liver.

Authors:  Marek Waluga; Michał Kukla; Michał Żorniak; Agata Bacik; Rafał Kotulski
Journal:  World J Hepatol       Date:  2015-08-28

4.  Long-term effects and benefits of Helicobacter pylori eradication on the gastric mucosa in older individuals.

Authors:  Jie Chen; Gansheng Zhang; Jian Qin; Yiqin Huang; Yu Wang; Zhongkuo Li; Danian Ji; Li Xiao; Shuming Yin; Zhijun Bao
Journal:  Saudi J Gastroenterol       Date:  2022 Mar-Apr       Impact factor: 2.485

5.  Seroprevalence of Helicobacter pylori among dyspeptic patients in northern Lebanon: a 6-year retrospective study in two tertiary hospitals.

Authors:  Mohamad Bachar Ismail; Marwan Osman; Elie Bou Raad; Marcel Achkar; Monzer Hamze
Journal:  Access Microbiol       Date:  2022-04-27

Review 6.  Role of Helicobacter pylori infection in the manifestation of old age-related diseases.

Authors:  Abolfazl Zendehdel; Maryam Roham
Journal:  Mol Genet Genomic Med       Date:  2020-02-17       Impact factor: 2.183

7.  Relationship Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease (NAFLD) in a Developing Country: A Cross-Sectional Study.

Authors:  Yousry Esam-Eldin Abo-Amer; Aisha Sabal; Rehab Ahmed; Nabil Fathy Esmael Hasan; Rasha Refaie; Sahar Mohamed Mostafa; Ahmed Abdelhaleem Mohamed; Mahmoud Khalil; Waleed Elagawy; Sherief Abd-Elsalam
Journal:  Diabetes Metab Syndr Obes       Date:  2020-03-02       Impact factor: 3.168

8.  Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study.

Authors:  Wen Gao; Hui Ye; Xin Deng; Chi Wang; Ying Xu; Yixuan Li; Xuezhi Zhang; Hong Cheng
Journal:  Helicobacter       Date:  2020-06-16       Impact factor: 5.753

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.